| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15988fb449170a97f0b12beafad88bca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-70 |
| filingDate |
1988-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1991-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42f7d60691b3128066d3a5026fecbd08 |
| publicationDate |
1991-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5051264-A |
| titleOfInvention |
Potentiation of the thrombolytic effect of prourokinase type plasminogen activators by streptokinase |
| abstract |
The thrombolytic effect of known plasminogen activators such as tissue plasminogen activator (t-PA), prourokinase and modifications of t-PA and prourokinase is enhanced dramatically and unexpectedly when combined with streptokinase. The body is treated with a combination streptokinase and one or more plasminogen activators of the t-PA or prourokinase type to achieve an enhanced effect which has advantage in thrombolytic therapy including the treatment of myocardial infarction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7076287-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9211317-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002087055-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10112989-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5776498-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11034755-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011229454-A1 |
| priorityDate |
1988-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |